Texas Yale Capital Corp’s Editas Medicine EDIT Stock Holding History

Texas Yale Capital Corp’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-70,000	Closed	-$144K	–	508
2025 Q4	$144K	Hold	70,000	–	–	﹤0.01%	486
2025 Q3	$243K	Hold	70,000	–	–	0.01%	439
2025 Q2	$154K	Hold	70,000	–	–	0.01%	456
2025 Q1	$81.2K	Hold	70,000	–	–	﹤0.01%	443
2024 Q4	$88.9K	Hold	70,000	–	–	﹤0.01%	453
2024 Q3	$239K	Hold	70,000	–	–	0.01%	422
2024 Q2	$327K	Hold	70,000	–	–	0.02%	364
2024 Q1	$519K	Hold	70,000	–	–	0.02%	324
2023 Q4	$709K	Hold	70,000	–	–	0.03%	284
2023 Q3	$546K	Hold	70,000	–	–	0.02%	300
2023 Q2	$576K	Hold	70,000	–	–	0.03%	298
2023 Q1	$508K	Hold	70,000	–	–	0.03%	322
2022 Q4	$621K	Hold	70,000	–	–	0.04%	301
2022 Q3	$857K	Hold	70,000	–	–	0.05%	250
2022 Q2	$828K	Buy	70,000 +20,000	+40%	+$268K	0.05%	254
2022 Q1	$951K	Buy	50,000 +10,000	+25%	+$186K	0.05%	245
2021 Q4	$1.06M	Buy	40,000 +15,000	+60%	+$516K	0.05%	241
2021 Q3	$1.03M	Buy	25,000 +5,000	+25%	+$274K	0.06%	237
2021 Q2	$1.13M	Hold	20,000	–	–	0.06%	225
2021 Q1	$840K	Buy	20,000 +10,000	+100%	+$570K	0.05%	253
2020 Q4	$701K	Buy	+10,000	New	+$411K	0.05%	275

Other funds holding EDIT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Texas Yale Capital Corp's EDIT Position: Q1 2026 in Review

Texas Yale Capital Corp sold out of Editas Medicine (EDIT) in Q1 2026, closing a stake of 70,000 shares — an estimated $144K sold.

Texas Yale Capital Corp first reported a position in EDIT in Q4 2020 and held it in 21 quarters. The position peaked at $1.13M in Q2 2021. 208 funds tracked by Wall St. Rank hold EDIT as of Q1 2026.

Texas Yale Capital Corp reported no remaining Editas Medicine position as of Q1 2026 after selling out during the quarter.
Texas Yale Capital Corp sold 70,000 Editas Medicine shares in Q1 2026, an estimated $144K.
Texas Yale Capital Corp first reported a position in Editas Medicine in Q4 2020 and held it in 21 quarters.
Texas Yale Capital Corp's Editas Medicine position peaked at $1.13M in Q2 2021.
208 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2026.

Based on Texas Yale Capital Corp's 13F filing for Q1 2026, filed 4 May 2026.